Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Aldeyra Therapeutics, Inc. (ALDX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 SC 13G Knoll Capital Management, LLC reports a 6.1% stake in Aldeyra Therapeutics Inc
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/03/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
06/29/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aldeyra Therapeutics, Inc. Presentation",
"Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX‑2191 in Patients with Retinitis Pigmentosa"
05/23/2023 ARS Form ARS - Annual Report to Security Holders:
05/23/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
03/09/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/09/2023 10-K Annual Report for the period ended December 31, 2022
03/09/2023 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights"
03/02/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma"
02/14/2023 SC 13G/A PERCEPTIVE ADVISORS LLC reports a 19.4% stake in Aldeyra Therapeutics, Inc.
02/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease"
02/03/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
12/27/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Second Amendment to Loan and Security Agreement, and effective as of December 31, 2022, by and among Aldeyra Therapeutics, Inc., Helio Vision, LLC, the several banks and other financial institutions or entities from time to time parties thereto and Hercules Capital, Inc"
12/21/2022 8-K Quarterly results
12/01/2022 8-K Quarterly results
11/29/2022 8-K Quarterly results
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
10/06/2022 8-K Quarterly results
09/14/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate Milestones Dry Eye Disease NDA for Reproxalap Expected to be Submitted in the Fourth Quarter of 2022 Pre-NDA Meeting for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma Scheduled for the Fourth Quarter of 2022 Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy Expected in the Third or Fourth Quarter of 2022 Results from the Phase 2 Clinical Trial of ADX-2191 in Retinitis Pigmentosa Expected in the First Half of 2023 Results from the Phase 3 INVIGORATE-2 Trial of Reproxalap in Allergic Conjunctivitis Expected in 2023"
08/05/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/05/2022 8-K Quarterly results
07/12/2022 8-K Quarterly results
07/08/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
06/08/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/18/2022 8-K Quarterly results
05/05/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/05/2022 8-K Quarterly results
04/28/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Aldeyra Therapeutics Announces Chief Financial Officer Transition"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy